SCHEMBL13014308

SCHEMBL13014308

CC(C)(C)OC(=O)CNC(Cc1ccc([N+](=O)[O-])cc1)CN1CCN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
LMNA P02545 3/20 0.40
MAPT P10636 2/20 0.40
KCNJ1 P48048 6/20 0.39
KCNH2 Q12809 5/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39
NR1D1 P20393 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
MAPK1 P28482 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
NR2F2 P24468 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18118462 0.94 LMNA (0.39) ALDH1A1LMNAMAPTKCNJ1KCNH2
SCHEMBL17510894 0.90 ITGA4 (0.37) ALDH1A1LMNAMAPTKCNJ1KCNH2
SCHEMBL13014216 0.86 F2 (0.35) ALDH1A1MAPTL3MBTL1MAPK1NPC1
SCHEMBL16731704 0.83 HRH2 (0.41) ALDH1A1LMNAMAPTKCNJ1KCNH2
SCHEMBL3259997 0.82 F2 (0.35) OPRK1
SCHEMBL1150117 0.80 NR1D1 (0.44) ALDH1A1LMNAMAPTKCNJ1KCNH2
SCHEMBL13014128 0.80 NR1D1 (0.44) ALDH1A1LMNAMAPTKCNJ1KCNH2
SCHEMBL463473 0.80 LMNA (0.44) ALDH1A1LMNAKCNJ1KCNH2L3MBTL1
SCHEMBL13014204 0.80 MEN1 (0.46) MAPTNPC1RAB9AOPRK1
SCHEMBL16656263 0.80 KDM4E (0.56) ALDH1A1LMNAMAPTKCNJ1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115094-B2 Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using THE UNITED STATES OF AMERICA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) (US) 2015-08-25 US disclosed
US-9115094-B2 Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using THE UNITED STATES OF AMERICA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) (US) 2015-08-25 US disclosed
US-20100322855-A1 Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using ILLINOIS INSTITUTE OF TECHNOLOGY (US) 2010-12-23 US disclosed
US-20100322855-A1 Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using ILLINOIS INSTITUTE OF TECHNOLOGY (US) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100322855-A1 Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using UACA, CLTC, PKD1 ALDH1A1 3456/4885LMNA 559/4885MAPT 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.